5mg, 10mg, 15mg & 20mg tablets

Approved as an option for treating symptomatic obstructive hypertrophic cardiomyopathy in adults who have a New York Heart Association class of 2 to 3 in line with NICE and NHSE Specialised Commissioning guidance.

It is recommended only if it is an add‑on to individually optimised standard care that includes beta‑blockers, non-dihydropyridine calcium-channel blockers or disopyramide, unless these are contraindicated.

2.5 mg, 5mg, 10mg, 15mg hard capsules

Approved as an option for treating symptomatic obstructive hypertrophic cardiomyopathy in adults who have a New York Heart Association class of 2 to 3 in line with NICE and NHSE Specialised Commissioning guidance.

It is recommended only if it is an add‑on to individually optimised standard care that includes beta‑blockers, non-dihydropyridine calcium-channel blockers or disopyramide, unless these are contraindicated.

The following providers are commissioned to provide this service:

• North Cumbria Integrated Care NHS Foundation Trust
• South Tees Hospitals NHS Foundation Trust
• The Newcastle upon Tyne Hospitals NHS Foundation Trust